Tivic Health Systems (Nasdaq: TIVC) submitted a new patent application (No. 63,801,058) to the USPTO, protecting innovations in personalized stimulation parameters and electrode placement for its non-invasive vagus nerve stimulation (VNS) system. This filing builds on patents granted in 2024 across the U.S. and Europe.
The technology aims to deliver more consistent and enhanced therapeutic effects, based on insights from a recent VNS optimization study. Tivic completed enrollment in this study in November 2024.
In April, Tivic engaged with the White House and FDA to discuss its clinical pipeline, including its non-invasive cervical VNS device. CEO Jennifer Ernst emphasized the potential impact for military personnel, first responders, and the wider population as the company advances toward FDA approval.
Tivic plans to release Q1 2025 financial results on May 15.
Follow MEDWIRE.AI for medical device patent and regulatory news.
